<DOC>
	<DOCNO>NCT01785888</DOCNO>
	<brief_summary>This non-interventional diagnostic , international , multicenter non-comparative study EGFR mutation status aNSCLC patient ( locally advance and/or metastatic disease ) adenocarcinoma non-adenocarcinoma histology . This study conduct Japan Europe ass concordance EGFR mutation status derive tumour sample blood base circulate free DNA . The data generate inform use less-invasive sample type diagnostic practice . The study also aim assess current status EGFR mutation test across Japan Europe gap currently available data include EGFR mutation frequency particular population demographic subgroup , EGFR mutation frequency histological subtypes NSCLC , EGFR mutation test process methodology , utility multiple sample type assessment EGFR mutation status , impact EGFR mutation status therapy choice . The data may use drive improvement EGFR mutation test process , ensure patient access test treat appropriately basis molecular feature disease .</brief_summary>
	<brief_title>Europe-Japan Diagnostic Study EGFR Testing</brief_title>
	<detailed_description>A diagnostic Study European Japanese advance NSCLC patient evaluate suitable sample type EGFR testing ,</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients age 18 year old Europe age 20 year old Japan Histological cytological confirm locally advanced NSCLC ( stage IIIA/B ) suitable curative treatment metastatic ( stage IV ) NSCLC . Newly diagnose patient locally advance and/or metastatic NSCLC systemic treatment Na√Øve ( i.e . chemotherapy EGFRTKI ) patient recurrent disease previously receive adjuvant chemotherapy ( include EGFRTKI ) Provision diagnostic cancer tissue cytology sample upon inclusion Provision routine blood sample Evidence severe uncontrolled systemic disease Evidence significant clinical disorder laboratory find make undesirable patient participate study Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>EGFR ,</keyword>
	<keyword>aNSCLC ,</keyword>
	<keyword>mutation status ,</keyword>
	<keyword>diagnostic study ,</keyword>
	<keyword>Europe ,</keyword>
	<keyword>Japan</keyword>
</DOC>